Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression

Oncotarget

Volumn 7, Issue 3, 2016, Pages 2462-2474

  Li, Gong Quan ^a   Guo, Wen Zhi ^a   Zhang, Yi ^a,b   Seng, Jing Jing ^c   Zhang, Hua Peng ^a   Ma, Xiu Xian ^a   Zhang, Gong ^a   Li, Jie ^a   Yan, Bing ^a   Tang, Hong Wei ^a   Li, Shan Shan ^a   Wang, Li Dong ^a   Zhang, Shui Jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BIM; BRD4; HCC; JQ1; MYC

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BIM PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; (+)-JQ1 COMPOUND; AZEPINE DERIVATIVE; BRD4 PROTEIN, HUMAN; MESSENGER RNA; MYC PROTEIN; MYC PROTEIN, HUMAN; NUCLEAR PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIM GENE; BRD4 GENE; CANCER INHIBITION; CDKN1B GENE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; G1 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; ONCOGENE MYC; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; DRUG SCREENING; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; AZEPINES; BCL-2-LIKE PROTEIN 11; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MICE; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRIAZOLES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962217151     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6275     Document Type: Article

References (34)

1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M and Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006; 24(26):4293-4300.
2. Mujtaba S, Zeng L and Zhou MM. Structure and acetyllysine recognition of the bromodomain. Oncogene. 2007; 26(37):5521-5527.
3. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, et al. Selective inhibition of BET bromodomains. Nature. 2010; 468(7327):1067-1073.
4. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011; 478(7370):524-528.
5. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi JW, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. Cell. 2011; 146(6):903-916.
6. Dawson MA, Kouzarides T and Huntly BJP. Targeting Epigenetic Readers in Cancer. New England Journal of Medicine. 2012; 367(7):647-657.
7. Loosveld M, Castellano R, Gon S, Goubard A, Crouzet T, Pouyet L, Prebet T, Vey N, Nadel B, Collette Y and Payet-Bornet D. Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL). Oncotarget. 2014; 5(10):3168-3172. doi: 10.18632/oncotarget.1873.
8. Herrmann H, Blatt K, Shi JW, Gleixner KV, Cerny-Reiterer S, Mullauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J and Valent P. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia (AML). Oncotarget. 2012; 3(12):1588-1599. doi: 10.18632/oncotarget.733.
9. Henssen A, Thor T, Odersky A, Heukamp L, El-Hindy N, Beckers A, Speleman F, AlthoffK, Schäfers S and Schramm A. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget. 2013; 4(11):2080. doi: 10.18632/oncotarget.1534.
10. Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, Gao YD, Cheng KA, Cohoon TJ, Qi J, Akbay E, Kimmelman AC, Kung AL, Bradner JE and Wong KK. Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer. Clinical cancer research. 2013; 19(22):6183-6192.
11. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MGM, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA and Bradner JE. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma (vol 24, pg 777, 2013). Cancer cell. 2014; 25(4):545-546.
12. Qiu HF, Jackson AL, Kilgore JE, Zhong Y, Chang LLY, Gehrig PA, Zhou CX and Bae-Jump VL. JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer. Oncotarget. 2015; 6(9):6915-6930. doi: 10.18632/oncotarget.3126.
13. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S and Engelke C. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014; 510(7504):278-282.
14. Park IY, Sohn BH, Yu E, Suh DJ, Chung YH, Lee JH, Surzycki SJ and Lee YIK. Aberrant epigenetic modifications in-hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology. 2007; 132(4):1476-1494.
15. Thorgeirsson SS and Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nature genetics. 2002; 31(4):339-346.
16. Shukla SD and Aroor AR. Epigenetic effects of ethanol on liver and gastrointestinal injury. World Journal of Gastroenterology. 2006; 12(33):5265-5271.
17. Farazi PA and DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nature Reviews Cancer. 2006; 6(9):674-687.
18. Schlaeger C, Longerich T, Schiller C, Bewerunge P, Mehrabi A, Toedt G, KleeffJ, Ehemann V, Eils R, Lichter P, Schirtnacher P and Radwimmer B. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology. 2008; 47(2):511-520.
19. Lin C-P, Liu C-R, Lee C-N, Chan T-S and Liu HE. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World journal of hepatology. 2010; 2(1):16.
20. Kawate S, Fukusato T, Ohwada S, Watanuki A and Morishita Y. Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology. 1999; 57(2):157-163.
21. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013; 3(3):308-323.
22. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI and Young RA. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013; 153(2):320-334.
23. Zhang P, Dong Z, Cai J, Zhang C, Shen Z, Ke A, Gao D, Fan J and Shi G. BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Immunopathol Pharmacol. 2015; 28(1):36-44.
24. Rodriguez A, Jung EJ, Yin Q, Cayrol C and Flemington EK. Role of c-myc regulation in Zta-mediated induction of the cyclin-dependent kinase inhibitors p21 and p27 and cell growth arrest. Virology. 2001; 284(2):159-169.
25. Gallagher SJ, Mijatov B, Gunatilake D, Tiffen JC, Gowrishankar K, Jin L, Pupo GM, Cullinane C, Prinjha RK, Smithers N, McArthur GA, Rizos H and Hersey P. The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells. The Journal of investigative dermatology. 2014; 134(11):2795-2805.
26. Patel AJ, Liao C-P, Chen Z, Liu C, Wang Y and Le LQ. BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. Cell Reports. 2014; 6(1):81-92.
27. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S and Romieu-Mourez R. Repression of transcription of the p 27 Kip 1 cyclindependent kinase inhibitor gene by c-Myc. Oncogene. 2001; 20(14):1688-1702.
28. Albrecht JH, Poon RY, Ahonen CL, Rieland BM, Deng C and Crary GS. Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. Oncogene. 1998; 16(16):2141-2150.
29. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L and Sims RJ. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(40):16669-16674.
30. Cheng ZX, Gong YY, Ma YF, Lu KH, Lu X, Pierce LA, Thompson RC, Muller S, Knapp S and Wang JL. Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma. Clinical cancer research. 2013; 19(7):1748-1759.
31. Zhang SJ, Li GQ, Ma XX, Wang Y, Liu GZ, Feng LS, Zhao YF, Zhang G, Wu Y, Ye XX, Qin BM and Lu JF. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cellular signalling. 2012; 24(9):1803-1809.
32. Coude MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, Raffoux E, Itzykson R, Delord M, Riveiro ME, Herait P, Baruchel A, Dombret H and Gardin C. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget. 2015; 6(19):17698-17712. doi:10.18632/oncotarget.4131.
33. Trabucco SE, Gerstein RM, Evens AM, Bradner JE, Shultz LD, Greiner DL and Zhang H. Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma. Clinical cancer research. 2015; 21(1):113-122.
34. Zhang S, Li G, Zhao Y, Liu G, Wang Y, Ma X, Li D, Wu Y and Lu J. Smac mimetic SM-164 potentiates APO2L/TRAIL-and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells. PLoS ONE. 2012; 7(12):e51461.